Management to host conference call on Thursday, May 9, 2024, at 8:30 a.m. ET FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical...
FLORHAM PARK, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign
Phathom Pharmaceuticals today debuted its first effort for erosive esophagitis treatment Voquezna with a splashy direct-to-consumer campaign including a telehealth option.
National TV and digital media campaign aims to motivate millions of people suffering from Erosive GERD to learn more about VOQUEZNA® (vonoprazan), the first and only FDA-approved potassium-competitive acid blocker (PCAB)
Phathom Reports Fourth Quarter and Full Year 2023 Financial Results
Phathom to Report Fourth Quarter and Full Year 2023 Financial Results
Phathom Pharma to Report Fourth Quarter and Full Year 2023 Financial Results
Insider Traders Lose US$55k As Phathom Pharmaceuticals Drops
One of the largest pharmacy benefit management (PBM) companies in the United States has added VOQUEZNA (vonoprazan) tablets to its national formularies for commercial plans, effective immediately ...